A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

The Centers for Disease Control and Prevention hasn’t opened up the ordering process, raising concerns about delays as vaccination programs kick off.

Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.

/PRNewswire/ -- The G. and R. Loeb Foundation Inc. and UCLA Anderson School of Management today announced the career honorees and 42 competition finalists for...

Heidi Overton, a doctor and White House adviser, is expected to be President Trump's pick to lead the FDA.

The Republican senator’s office published over 20 individuals’ health information without redaction.

Doctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.

Doctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.

Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.

The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.

FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.

LifeMD, a popular telehealth company, has been accused by former employees of pressing clinicians to mete out prescriptions more rapidly without sufficient screening and follow-up.

After his predecessor's turbulent tenure, Karim Mikhail is working to restore staff morale and revisit controversial rejections.

Family caregivers of people with disabilities face a grim financial future as several states consider steep cuts to their wages.

In a private meeting, HHS officials met with mental health professionals to work on guidance for stopping SSRIs.

We talk with STAT News reporter Lizzy Lawrence about the agency’s recent turmoil and its hunt for a new leader.

How a father’s quest may shape the future of rare disease gene therapy.

The White House is reviewing finalists for FDA commissioner, suggesting the highly anticipated decision may come soon.

America’s employer-based health insurance system is crumbling in slow motion. See how, and why, in STAT's 8-part series 'Out of Pocket, Out of Reach.'

The Supreme Court handed down its last decisions of its 2025-26 term this week, including in an immigration case that could result in the loss of hundreds of thousands of workers in nursing homes and ...

The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.

The panel will soon consider whether to relax restrictions on certain peptides.

A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary hypertension.

The unusual access to an experimental drug has captured the attention of the American public as well.

Drugmaker Eli Lilly and the U.S. Food and Drug Administration have granted access to retatrutide to one man, through the FDA’s so-called “compassionate use” program.

Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency’s “compassionate use” program.

Federal health officials aim to speed up drug development and better compete with China.

The FDA said it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents.

As predicted, the expiration of enhanced tax subsidies for Affordable Care Act health plans is causing many people to lose coverage for failing to make premium payments. Meanwhile, Health and Human Se...

The FDA has approved a drug that was previously caught in a dispute between career staff and the political appointee head of the CDER.

The White House has used the program to reward companies that help its political goals.

About STAT In November 2015, STAT was launched as a new national media brand focused on health, medicine, and life sciences. Since then, we have grown to

WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top

The acting director of the FDA’s drug center, Tracy Beth Høeg, is leaving the agency. The news come days after Commissioner Marty Makary handed in his resignation.

Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval reforms.

Sen. Bill Cassidy risked his legacy. It may not be enough to save his career.

Here is a running list of senior FDA officials who have left the agency recently.

Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.

Alcohol kills more Americans each year than all other drugs combined. Why does the U.S. ignore its most harmful substance use crisis? Alcohol kills more

Makary's ouster would create another high-profile vacancy atop RFK Jr.'s health department.

In this week's STATus Report, hear from six former FDA officials on why they left the agency.

What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.

Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.

Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.